Eugia Pharma receives USFDA approval for Vasopressin Injection

19 Aug 2022 , 01:34 AM

Aurobindo Pharma announced that its wholly owned subsidiary company Eugia Pharma Specialties has received a final approval from the US Food Drug Administration USFDA to manufacture and market Vasopressin Injection USP 20 UnitsmL Multiple-Dose Vials Vasopressin Injection USP 20 UnitsmL Multiple-Dose Vials to be bioequivalent and therapeutically equivalent to the reference listed drug RLD Vasostrict Injection 20 unitsmL of Par Sterile Products LLC Par The product is being launched Immediately The approved product has an estimated market size of around US$ 606 million for the twelve months ending June 2022 according to IQVIA This is the 146th ANDA including 10 tentative approvals received out of Eugia Pharma Speciality Group EPSG facilities manufacturing both oral and sterile specialty products Vasopressin Injection USP is indicated for the treatment of Cardiovascular agent vasoconstrictor Indicated to increase blood pressure in adults with vasodilatory shock eg post-cardiotomy or sepsis who remain hypotensive despite fluids and catecholamines